Observational Study of Routine Ophthalmological Examinations of Patients Included in the 2 Bayer Sponsored Phase 3 Clinical Trials FIDELIO and FIGARO to Investigate the Effect of Finerenone on Delaying the Progression of Diabetic Retinopathy
Latest Information Update: 26 Aug 2022
At a glance
- Drugs Finerenone (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms ReFineDR
- Sponsors Bayer; Bayer Yakuhin
- 21 Nov 2021 Status changed from recruiting to completed.
- 16 Oct 2020 Planned primary completion date changed from 31 Mar 2021 to 29 Oct 2021.
- 14 Aug 2020 Status changed from not yet recruiting to recruiting.